
doi: 10.1002/bit.27819
pmid: 33990942
AbstractHere, we report a bienzymatic cascade to produce β‐amino acids as an intermediate for the synthesis of the leading oral antidiabetic drug, sitagliptin. A whole‐cell biotransformation using recombinant Escherichia coli coexpressing a esterase and transaminase were developed, wherein the desired expression level of each enzyme was achieved by promotor engineering. The small‐scale reactions (30 ml) performed under optimized conditions at varying amounts of substrate (100–300 mM) resulted in excellent conversions of 82%–95% for the desired product. Finally, a kilogram‐scale enzymatic reaction (250 mM substrate, 220 L) was carried out to produce β‐amino acid (229 mM). Sitagliptin phosphate was chemically synthesized from β‐amino acids with 82% yield and > 99% purity.
Sitagliptin Phosphate, Escherichia coli, Esterases, Microorganisms, Genetically-Modified, Genetic Engineering, Promoter Regions, Genetic, Transaminases
Sitagliptin Phosphate, Escherichia coli, Esterases, Microorganisms, Genetically-Modified, Genetic Engineering, Promoter Regions, Genetic, Transaminases
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 15 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
